Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nancy Kaplitz

Neurology Key West, FL Medical Doctor

NPI 1033258587 CMS profile 273860

1111 12Th St, Suite 110, Key West, FL 33040

Open in the dashboard

General payments

$967

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Kaplitz of Key West, FL is reported in the CMS Open Payments database as having received $967 across 18 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 44th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52 2
2023 General $389 4
2022 General $152 2
2021 General $55 3
2020 General $139 2
2019 General $180 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Kaplitz
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Nancy Kaplitz were reported at $52. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Nancy Kaplitz Neurology median Middle half National median
2019 $180 $474 $118–$2,177 $163
2020 $139 $367 $82–$2,309 $114
2021 $55 $438 $104–$2,547 $132
2022 $152 $442 $103–$2,388 $149
2023 $389 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $52 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $241 2 payments
  2. AbbVie, Inc. $156 2 payments
  3. Nevro Corp. $152 2 payments
  4. Idorsia Pharmaceuticals US Inc $125 1 payment
  5. Genentech, Inc. $112 1 payment
  6. Allergan Inc. $57 4 payments
  7. Lilly USA, LLC $37 2 payments
  8. Biogen, Inc. $26 1 payment
  9. Mitsubishi Tanabe Pharma America, Inc. $25 1 payment
  10. Pfizer Inc. $22 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $967 18 payments
Products named General payments · program years 2019–2025
  1. Omnia $152 2 payments
  2. VRAYLAR $125 1 payment
  3. INGREZZA Neurology $125 1 payment
  4. QUVIVIQ $125 1 payment
  5. INGREZZA Neuropsychiatry $116 1 payment
  6. Ongentys $116 1 payment
  7. OCREVUS $112 1 payment
  8. BOTOX Hyperhydrosis $57 4 payments
  9. EMGALITY $37 2 payments
  10. BOTOX Botox Therapeutic $31 1 payment
  11. Other $97 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

248

Median for Neurology: 833

Drug cost

$3,579

Median for Neurology: $202,670

Branded share of claims

27.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 89 $1,155
Sumatriptan Succinate Generic 17 $693
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 22 $474
Carbidopa-Levodopa Carbidopa/Levodopa Brand 15 $307
Levetiracetam Er Levetiracetam Brand 18 $235
Alprazolam Generic 16 $199
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $158
Clonazepam Generic 13 $120
Lorazepam Generic 21 $120
Lisinopril Generic 13 $104

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$82,536

Of which drugs: $12,521

Medicare patients

139

Average age 73

Services billed

3,331

69 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 29%
Depression 24%
Diabetes 22%
Atrial fibrillation 20%
Cancer 14%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 50 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record